Detection of promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients

Annals of the New York Academy of Sciences
Paul Cairns

Abstract

Kidney cancer is curable by surgical resection and therapy, if detected at an early stage. Using sensitive methylation-specific polymerase chain reaction, we screened matched tumor DNA and preoperative urine DNA from 50 kidney cancer patients, for hypermethylation of a panel of six normally unmethylated tumor suppressor genes: VHL, p16/CDKN2a, p14ARF, APC, RASSF1A, and Timp-3. When compared to the tumor DNA, an identical pattern of gene hypermethylation was found in the matched urine DNA from 44 of 50 patients (88% sensitivity) including 27 of 30 cases of stage I disease. By contrast, hypermethylation was not observed in normal and benign disease controls (100% specificity). We conclude that promoter hypermethylation is a common and early event in kidney tumorigenesis and can be detected in the urine DNA from patients with organ-confined renal cancer of all histologic types.

References

Sep 19, 1996·The New England Journal of Medicine·R J MotzerD M Nanus
Sep 3, 1996·Proceedings of the National Academy of Sciences of the United States of America·J G HermanS B Baylin
Feb 13, 1999·Nature Genetics·P A Jones, P W Laird
May 18, 2001·Nature·J Taipale, P A Beachy
May 7, 2002·Nature Reviews. Cancer·David Sidransky
Sep 3, 2002·Cancer Cell·Charles J Sherr, Frank McCormick

❮ Previous
Next ❯

Citations

Mar 6, 2012·Cancer Letters·Maria J WorshamVanessa G Schweitzer
Jul 14, 2010·Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery·Maria J WorshamMichael S Benninger
Jul 20, 2006·Journal of the National Cancer Institute·Mohammad Obaidul HoqueDavid Sidransky
Sep 12, 2009·PloS One·Angela CannasUNKNOWN TB trDNA consortium
Sep 26, 2013·International Journal of Molecular Sciences·Yahya I ElshimaliJaydutt V Vadgama
Jul 21, 2005·Nutrition Reviews·Dale C McCabe, Marie A Caudill
Feb 15, 2011·Clinical Epigenetics·Josena K StephenMaria J Worsham
Dec 2, 2006·Urologic Oncology·Robert W Veltri, Danil V Makarov
Oct 8, 2008·Annals of the New York Academy of Sciences·Ying-Hsiu SuTimothy M Block
Apr 8, 2014·The Journal of Urology·Fei LianJohn A Petros
Mar 4, 2006·Expert Review of Molecular Diagnostics·Samuil R Umansky, L David Tomei
Apr 11, 2013·Expert Review of Molecular Diagnostics·Surbhi JainYing-Hsiu Su
Aug 20, 2014·Expert Review of Molecular Diagnostics·Angela A GuzzettaNita Ahuja
Apr 16, 2017·Molecular Cancer·Ashley Di MeoGeorge M Yousef
Jun 6, 2007·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Qinghua FengNancy B Kiviat
Jun 3, 2021·Cancers·Masanori OshiKazuaki Takabe

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Hojoong KimDuk-Hwan Kim
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Essel DulaimiPaul Cairns
© 2022 Meta ULC. All rights reserved